Joseph Segal is a 96-year-old World War II vet and renowned business tycoon. As the founder of Fields stores and President of Kingswood Capital Corporation, Joseph Segal has built an […]
Adolescence can be a challenging time to manage type 1 diabetes (T1D). Life (and hormones!) change in all sorts of ways, and many teenagers experience higher than recommended blood glucose […]
Canada holds a special place in the story of insulin because scientists Banting and Best made the discovery at the University of Toronto, in 1921. Before the discovery, the lives […]
This June, Canadians from coast to coast will be coming together to unite, raise funds and help accelerate the pace of type 1 diabetes (T1D) research as part of the […]
Federal Budget Includes New Funding for Type 1 Diabetes Research, National Diabetes Framework and Expanded Access to Disability Tax Credit
JDRF Canada is thrilled that federal budget 2021 includes new funding for type 1 diabetes research, as well as support for a national diabetes framework and improvements to the Disability […]
May 4th, 2021 “Insulin is not a cure for diabetes; it is a treatment.” – Dr. Frederick Banting 2021 marks the 100th anniversary of the discovery of insulin by researchers […]
Update: May 3, 2021: Ontario: As of May 10, 2021 anyone over 16 with type 1 diabetes can book a vaccine throughout the province. Alberta: Children aged 12 -15 with type 1 […]
May 4th, 2021 On April 15, 2021 the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for vTv Therapeutics’ TTP399 as an adjunct therapy to insulin for type 1 diabetes […]
April 19, 2021 JDRF was founded over 40 years by a group of devoted parents to provide a voice for the type 1 diabetes (T1D) community – and with the […]
April 9, 2021 Volunteers can often be unsung heroes of an organization, but they help drive a mission forward with unparalleled dedication and perseverance, especially the volunteers at JDRF. And […]
100 years after the discovery of insulin, JDRF is pleased to announce the results of the first annual Beyond Insulin Vote for Research.
JDRF’s mission of improving lives and curing type 1 diabetes (T1D) cannot be achieved alone. It requires us to engage with stakeholders who believe in what we have set out to do and are able to help drive our mission forward – and this group includes regulators. JDRF recognizes the importance of engaging with regulators in order to to help shape and provide clear and reasonable pathways to scientific research and therapy approvals for T1D treatment and cure therapies.